Search Results - "Leichman, L P"

Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer by Ilson, DH, Wadleigh, RG, Leichman, LP, Kelsen, DP

“…Background: The purpose of the study was to evaluate the efficacy of weekly paclitaxel (Taxol) in advanced esophageal cancer. Patients and methods: One hundred…”
Get full text

p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival by LENZ, H.-J, HAYASHI, K, LEICHMAN, C. G, SALONGA, D, DANENBERG, K. D, DANENBERG, P. V, METZGER, R, BANERJEE, D, BERTINO, J. R, GROSHEN, S, LEICHMAN, L. P

“…Recent studies suggest that there may be a strong correlation between the p53 status of a tumor and a patient's response to chemotherapy. Therefore, we…”
Get full text

p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site by LENZ, H.-J, DANENBERG, K. D, LEICHMAN, C. G, FLORENTINE, B, JOHNSTON, P. G, GROSHEN, S, LINYUN ZHOU, YI PING XIONG, DANENBERG, P. V, LEICHMAN, L. P

“…We initiated a retrospective study to determine whether p53 status and thymidylate synthase (TS) protein expression in primary colon tumors influence…”
Get full text

A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer by Saltz, L B, Leichman, C G, Young, C W, Muggia, F M, Conti, J A, Spiess, T, Jeffers, S, Leichman, L P

“…UFT is a fixed-ratio combination of uracil and Ftorafur, a prodrug that is absorbed orally and metabolized in vivo to 5-fluorouracil (5-FU). Uracil potentiates…”
Get more information

High frequency of simultaneous loss of p16 and p16β gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach by HAYASHI, K, METZGER, R, LENZ, H.-J, DANENBERG, P. V, SALONGA, D, DANENBERG, K, LEICHMAN, L. P, FINK, U, SENDLER, A, KELSEN, D, SCHWARTZ, G. K, GROSHEN, S

“…Quantitative reverse transcription PCR (RT-PCR) was used to measure gene expressions (relative mRNA levels) of p16 and the alternate transcript p16β in…”
Get full text

Failure of Pretreatment With Intravenous Folic Acid to Alter the Cumulative Hematologic Toxicity of Lometrexol by MUGGIA, FRANCO M., SYNOLD, TIMOTHY W., NEWMAN, EDWARD M., JEFFERS, SUSAN, LEICHMAN, LAWRENCE P., DOROSHOW, JAMES H., JOHNSON, KAY, GROSHEN, SUSAN

“…In a study, 5 mg folic acid was given intravenously one hour before lometrexol every three weeks. The failure of pretreatment with intravenous folic acid to…”
Get full text

Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group experience by Seydel, H G, Stablein, D M, Leichman, L P, Kinzie, J J, Thomas, P R

“…Eighteen patients with unresectable localized adenocarcinoma of the pancreas were treated by a combination of chemotherapy plus hyperfractionated radiation…”
Get more information

Celestin tube use: radiographic manifestations of associated complications by Haynes, J W, Miller, P R, Steiger, Z, Leichman, L P, Kling, G A

“…Celestin intubation of the esophagus is occasionally employed in the palliation of unresectable esophageal carcinoma and in the obturation of malignant…”
Get more information

Phase I evaluation and pharmacokinetics of aziridinylbenzoquinone using a weekly intravenous schedule by SCHILCHER, R. B, YOUNG, J. D, LEICHMAN, L. P, HAAS, C. D, BAKER, L. H

“…Quinone derivatives have shown intensive antitumor activity in a broad variety of neoplasias. Aziridinylbenzoquinone is designed to have adequate lipid…”
Get full text

Chemotherapy for advanced epidermoid carcinoma of the esophagus with single-agent cisplatin: final report on a Southwest Oncology Group study by Panettiere, F J, Leichman, L P, Tilchen, E J, Chen, T T

Get more information

Phase II study of sorafenib with gemcitabine and erlotinib (GES) in first-line advanced pancreatic cancer by Cohen, D. J., Leichman, L. P., Love, E., Ryan, T., Leichman, C. G., Newman, E., Levinson, B., Hochster, H. S.

“…Abstract only 266 Background: Addition of erlotinib (E) to gemcitabine (G) results in improved OS for patients (pts) with advanced pancreatic cancer. Many…”
Get full text

Association of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative study (SWOG 0356) by Bohanes, P. O., Goldman, B. H., Benedetti, J., Blanke, C. D., Leichman, L. P., Iqbal, S., Thomas, C. R., Corless, C. L., Gold, P. J., Lenz, H.

“…Abstract only 2 Background: Preoperative platinum-based CRT for operable esophageal cancer has improved overall survival (OS) compared to surgery alone. The…”
Get full text

Association of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative group study (SWOG S0356) by Bohanes, P. O., Goldman, B. H., Leichman, L. P., Blanke, C. D., Iqbal, S., Thomas, C. R., Corless, C. L., Billingsley, K. G., Danenberg, K. D., Zhang, W., Benedetti, J. K., Gold, P. J., Lenz, H.

“…Abstract only…”
Get full text

A fixed-sequence, open-label study to determine the activity of SCH 717454 (robatumumab) as assessed by positron emission tomography in patients with relapsed or recurrent colorectal cancer by Lin, E. H., Lenz, H., Saleh, M. N., Badarinath, S., Knost, J. A., MacKenzie, M. J., Polite, B. N., Kavan, P., Chen, E. X., Leichman, L. P., Pathiraja, K., Lu, B. D.

“…Abstract only…”
Get full text

E2205: A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus by Gibson, M. K., Catalano, P. J., Kleinberg, L., Staley, C. A., Montgomery, E., Song, W., Mulcahy, M. F., Leichman, L. P., Benson, A. B.

“…Abstract only…”
Get full text

Cetuximab as second-line therapy in patients with metastatic esophageal cancer: A phase II Southwest Oncology Group Study by Gold, P. J., Goldman, B., Iqbal, S., Leichman, L. P., Lenz, H. J., Blanke, C. D.

“…Abstract only…”
Get full text

Phase II study of high-dose intermittent cycloleucine in colorectal malignancies by Dindogru, A, Leichman, L P, Cummings, G, Baker, L H

Get more information

Mitomycin C and bleomycin in the treatment of far-advanced cervical cancer: a Southwest Oncology Group pilot study by Leichman, L P, Baker, L H, Stanhope, C R, Samson, M K, Fraile, R J, Vaitkevicius, V K, Hilgers, R

“…Under the auspices of the Southwest Oncology Group, Wayne State University tested a schedule using bleomycin and mitomycin C that was previously reported to…”
Get more information

Methyl-GAG in advanced colon cancer: a phase II trial of the Southwest Oncology Group by Knight, 3rd, W A, Loesch, D M, Leichman, L P, Fabian, C, O'Bryan, R M

Get more information

Updated results of an exploratory gene expression analysis for primary esophageal cancer (PEC) patients (pts) treated with oxaliplatin (OXP), protracted infusion (PI) 5FU and radiation (XRT) by Leichman, L. P., Lawrence, D., Clark, K., Nava, H., Nava, E., Leichman, C. G., Proulx, G., Berdzik, J., Greco, W., Pendyala, L.

“…Abstract only…”
Get full text